Spain: New guidelines for conducting clinical investigations of medical devices

15 May 2023    2 minute read
Sectors Healthcare & Life Sciences
Clinic investigations Sanitary products Medical devices

In brief

The Spanish Medicines and Medical Devices Agency (AEMPS) has published new guidelines on how to conduct clinical investigations with medical devices, in order to adapt them to EU Regulation 2017/745 on the clinical investigation and sale of medical devices for human use. The main changes include adjustments to the requirements for approval of clinical investigations, modifications to the procedures, deadlines and the documentation required. The new guidelines took effect on 23 March 2023, together with the new Royal Decree 192/2023 on medical devices.

Contents

In more detail 

Context

The Spanish Agency of Medicines and Medical Products (AEMPS) has modified the procedure for applying for clinical investigation authorizations in order to bring them in line with Regulation 2017/745 on medical devices, as well as to introduce additional national requirements for sponsors. Furthermore, the new instructions are necessary for the correct implementation of the new Royal Decree 192/2023 on medical devices and the changes which it has introduced at national level regarding clinical investigations.

Requirements for the conduct of clinical investigations with medical devices

The new instructions have been published on the AEMPS website, and they differentiate between the following kinds of clinical investigations, which in turn are subject to different requirements:

  • Investigations regarding medical devices without European Conformity (CE) marking aimed to obtain product conformity assessment and investigations regarding CE marked medical devices for a new intended purpose: require prior authorization by the AEMPS, which is subject to a favorable opinion issued by an Ethics Committee. In addition, an agreement needs to be entered with the centers participating in the clinical investigation. 
  • Investigations regarding CE marked medical devices according to the approved intended purpose: do not require prior authorization by the AEMPS, but require a favorable opinion issued by an Ethics Committee as well as an agreement with the centers participating in the clinical investigation. Furthermore, if the clinical investigation involves invasive procedures, the sponsor shall be required to notify the Member States concerned at least 30 calendar days before the start of the procedure. In Spain, notifications shall be made to the AMEPS for inclusion in the Notifications of Observational Studies of Medical Devices (NEOPS) database until the European Database on Medical Devices (EUDAMED) electronic system is operational.
  • Other investigations with medical devices: the AEMPS must be consulted on the procedure to be followed, which will evaluate whether an authorization is needed.

Procedure and deadlines

The guidelines also include the process to be followed to apply for the research authorization and the documents that must accompany the request. Some of the most relevant differences between the previous and the current procedural requirements are as follow:

  • New deadlines have to be taken into account throughout the procedure: 10 days for the verification of the application by the AEMPS and 45 days for the evaluation. In addition, if the clinical investigation is temporarily halted or terminated prematurely, the sponsor must notify the AEMPS within 15 calendar days; or within 24 hours if this is due to safety reasons.
  • One year after the end of the investigation or three months later if the investigation is terminated early or temporarily interrupted, the sponsor must send a final report to the AEMPS. If the clinical investigation lasts longer than one year, the sponsor shall submit an annual report on the clinical investigation to the AEMPS.

For more information please access the guideline from the AEMPS through the following link.

Contact Information
Montserrat Llopart
Partner
Barcelona
Read my Bio
montserrat.llopart@bakermckenzie.com

Copyright © 2025 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.